Compare · CDIO vs NEOG
CDIO vs NEOG
Side-by-side comparison of Cardio Diagnostics Holdings Inc. (CDIO) and Neogen Corporation (NEOG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDIO and NEOG operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $2.54B, about 449.1x CDIO ($5.7M).
- Over the past year, CDIO is down 45.1% and NEOG is up 106.9% - NEOG leads by 152.0 points.
- NEOG has been more active in the news (11 items in the past 4 weeks vs 6 for CDIO).
- NEOG has more recent analyst coverage (5 ratings vs 0 for CDIO).
- Company
- Cardio Diagnostics Holdings Inc.
- Neogen Corporation
- Price
- $1.95-2.99%
- $11.65+0.52%
- Market cap
- $5.7M
- $2.54B
- 1M return
- +13.37%
- +24.87%
- 1Y return
- -45.07%
- +106.93%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 1989
- News (4w)
- 6
- 11
- Recent ratings
- 0
- 5
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest CDIO
- Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City
- SEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.
- SEC Form DEFA14A filed by Cardio Diagnostics Holdings Inc.
- SEC Form DEF 14A filed by Cardio Diagnostics Holdings Inc.
- Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026
- SEC Form PRE 14A filed by Cardio Diagnostics Holdings Inc.
- SEC Form 4 filed by Director Fung Peter K
- SEC Form 4 filed by Director Betts Wendy J
- SEC Form 4 filed by Director Intrater James
Latest NEOG
- SEC Form DEFA14A filed by Neogen Corporation
- SEC Form DEF 14A filed by Neogen Corporation
- Chief Accounting Officer Moylan John Patrick covered exercise/tax liability with 2,365 units of Restricted Stock Units, decreasing direct ownership by 7% to 29,331 units (SEC Form 4)
- CEO Nassif Mikheal covered exercise/tax liability with 20,397 units of Restricted Stock Units, decreasing direct ownership by 44% to 25,655 units (SEC Form 4)
- Chief Accounting Officer Moylan John Patrick was granted 8,584 units of Restricted Stock Units, increasing direct ownership by 36% to 32,155 units (SEC Form 4)
- Senior Vice President Ranalli Tamara A. was granted 25,751 shares (SEC Form 4)
- Chief Legal Officer Stacey Jennifer Evans was granted 38,627 shares (SEC Form 4)
- CFO Riggsbee Richard Bryan was granted 51,502 shares (SEC Form 4)
- CEO Nassif Mikheal was granted 141,631 shares (SEC Form 4)
- Neogen Corporation filed SEC Form 8-K: Leadership Update